🇺🇸 Rituximab - CHOP in United States

7 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 23 April 2025 – 23 April 2026
• Total reports: 7

Most-reported reactions

1. Epstein-Barr Virus Test Positive — 1 report (14.29%)
2. Mucosal Inflammation — 1 report (14.29%)
3. Non-Hodgkin'S Lymphoma Stage Iv — 1 report (14.29%)
4. Oral Herpes — 1 report (14.29%)
5. Pancytopenia — 1 report (14.29%)
6. Polyneuropathy — 1 report (14.29%)
7. Sepsis — 1 report (14.29%)

Source database →

Frequently asked questions

Is Rituximab - CHOP approved in United States?

Rituximab - CHOP does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Rituximab - CHOP in United States?

The Lymphoma Academic Research Organisation is the originator. The local marketing authorisation holder may differ — check the official source linked above.